Weicheng Guo - Sihuan Pharmaceutical Chairman
Chairman
Dr. Guo Weicheng is Chief Executive Officer, Executive Deputy Chairman of the Board of Sihuan Pharmaceutical Holdings Group Ltd. He was appointed to our Board on 18 May 2006 and is a cofounder of our Group. Dr. Guo is responsible for the overall operations of our Group, sales and marketing and our RD activities, with a focus on strategic planning, particularly in relation to mergers and acquisitions and product collaborations. He has also become responsible for Shenzhen Sihuans Pharmaceutical Co., Ltd. overall operations after it was acquired in 2007. Dr. Guo is instrumental to our Groups growth and business expansion since our establishment in 2001. Prior to our establishment, Dr. Guo had more than 4 years of experience as a general surgeon and more than 20 years of experience in the sales and marketing of pharmaceutical products. From 1992 to 1993, Dr. Guo held the position of chief surgeon in Guangzhou Military 177 Hospital. Dr. Guo was a surgeon and assistant lecturer at the Fourth Military Medical University, Tang Du Hospital, Xian City, PRC from 1986 to 1989 since 2014.
| Age | 59 |
| Tenure | 11 years |
| Phone | 852 3628 3911 |
| Web | https://www.sihuanpharm.com |
Sihuan Pharmaceutical Management Efficiency
Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Judy Schmeling | Canopy Growth Corp | 60 | |
| Ronald Funk | Aurora Cannabis | 63 | |
| CPA CPA | Procaps Group SA | 67 | |
| Michael Singer | Aurora Cannabis | 56 | |
| Jack Bendheim | Phibro Animal Health | 78 | |
| Mark Iwicki | Kala Pharmaceuticals | 59 | |
| Ruben Minski | Procaps Group SA | 72 | |
Management Performance
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 |
Sihuan Pharmaceutical Leadership Team
Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee | ||
| Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director | ||
| Yanling Chen, Joint Director | ||
| Guili Miao, Chief CEO | ||
| Kin Li, Joint Sec | ||
| Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee | ||
| Jionglong Zhang, Non-Executive Director | ||
| Chengkon Shih, General Manager of Shandong Xuanzhu | ||
| Feng Guo, Executive Director |
Sihuan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance |